Leqvio (Inclisiran) What to Expect: Week-by-Week in Your First Month

What Inclisiran Actually Does Before It Reaches Your Bloodstream

Inclisiran works at the level of messenger RNA, not circulating protein. After a subcutaneous injection, the drug is taken up primarily by hepatocytes via the asialoglycoprotein receptor (ASGR), which explains why liver tissue concentrations are far higher than plasma concentrations. Once inside the cell, inclisiran's small interfering RNA (siRNA) directs the RNA-induced silencing complex (RISC) to cleave the mRNA encoding PCSK9.

Why Silencing PCSK9 Matters

PCSK9 (proprotein convertase subtilisin/kexin type 9) tags LDL receptors on liver cell surfaces for degradation. When PCSK9 is silenced, those receptors recycle back to the surface. More surface LDL receptors means more LDL-C is cleared from circulation with each hepatic pass.

How siRNA Differs from Monoclonal Antibodies

Evolocumab (Repatha) and alirocumab (Praluent) block circulating PCSK9 protein. Inclisiran stops the protein from being made in the first place. That upstream blockade is why inclisiran's effect persists for roughly six months after a single injection while the antibody-based agents require dosing every two to four weeks. The RISC-loaded siRNA remains active inside the hepatocyte long after the parent drug clears plasma. [1]

The Injection Itself: What Happens on Day 1

The first injection is administered in a clinical setting, though home self-injection is possible after training. The injection volume is 1.5 mL delivered subcutaneously into the abdomen, upper arm, or thigh. The procedure takes under two minutes.

What You Will Feel During Administration

The needle is 27-gauge. Most patients describe mild pressure and occasionally a brief sting. No pre-medication is required. There is no need to fast beforehand, and you do not need to avoid statin doses around the injection. The drug can be given on the same day as your statin without any pharmacokinetic interaction.

Monitoring on Injection Day

Your provider will likely record your weight and blood pressure and confirm your most recent lipid panel. No observation period is mandated by the FDA label for outpatient settings, but most cardiology practices ask patients to wait 15 minutes to confirm no injection-site reaction develops. [2]

What the FDA Label Says About Administration

The FDA-approved prescribing information states inclisiran should be administered by a healthcare professional. The label also notes that if a dose is missed by more than three months, the patient should restart the regimen with a new Day 1 dose. [2]

Days 1 to 7: The Silent Phase

Nothing feels different in the first week. Inclisiran has no central nervous system activity, no appetite effects, and no hemodynamic action. You will not feel the drug "working."

What Is Happening Biochemically

Plasma PCSK9 levels begin to fall within 24 to 48 hours of the first dose as newly synthesized PCSK9 protein is no longer being produced at the same rate. In a single-dose ascending pharmacodynamic study published in the New England Journal of Medicine, PCSK9 concentrations fell by approximately 70% by day 14 after a single 300 mg dose. [3]

LDL-C itself lags behind the PCSK9 drop by roughly one to two weeks because the liver must first upregulate surface LDL receptor density before the clearance rate of circulating LDL particles accelerates.

Side Effects in Week 1

Injection-site reactions are the most common adverse event. In pooled ORION-10 and ORION-11 data (combined N=3,660 inclisiran-treated patients), injection-site reactions occurred in 8.2% of inclisiran patients versus 1.8% on placebo, and the large majority were mild and transient. [4] A small bruise or brief erythema in week one is the expected range. No systemic reactions attributable to the drug were documented at this time point in the Phase 3 program.

Weeks 2 to 4: The LDL-C Response Begins

By day 14, LDL-C reduction is measurable. Data from the Phase 1/2 ORION-1 trial showed a 27.9% LDL-C reduction as early as day 14 in patients receiving a 300 mg single dose. [3] The response accelerates through weeks three and four as more LDL receptors accumulate on the hepatocyte surface.

What Your Lipid Panel Shows at Week 4

At four weeks post-dose, most patients will see LDL-C reductions in the range of 30 to 40%. The full 50% effect takes longer, typically reaching its nadir at weeks 8 to 12. Your cardiologist may or may not order a lipid panel at the four-week mark; it is not required by any guideline. If you see a result in this window, expect it to be real but not yet maximal.

Triglycerides and HDL at Week 4

Inclisiran's primary action is on LDL-C. In ORION-10, triglycerides fell modestly (by approximately 14.5% vs. Placebo) and HDL-C increased by approximately 5.8%. [4] These secondary lipid changes are detectable by week 8 but are generally not a primary clinical target.

Liver Enzymes and Safety Markers

No clinically significant elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) were observed in ORION-10 at any time point. [4] You do not need a liver function test in month one unless your provider has another clinical reason to order one.

The Full First-Month Safety Profile: What Phase 3 Shows

The ORION-10 trial enrolled 1,561 patients with atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statin therapy and followed them for 510 days. ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents. Both trials were published together in the New England Journal of Medicine in 2020.

Efficacy Numbers from ORION-10 and ORION-11

In ORION-10, inclisiran reduced time-averaged LDL-C by 52.3% from baseline compared to placebo (P<0.0001). In ORION-11, the time-averaged reduction was 49.9% (P<0.0001). [4] The NEJM paper reports a pooled analysis showing 1,560 inclisiran-treated patients with a mean baseline LDL-C of approximately 105 mg/dL reaching a mean on-treatment LDL-C of approximately 50 mg/dL.

The trial authors wrote: "Inclisiran given twice yearly as an add-on to maximally tolerated statin therapy significantly reduced LDL cholesterol levels as compared with placebo, with a side-effect profile similar to that of placebo, except for injection-site reactions." [4]

Adverse Events Through Month 1

In the pooled Phase 3 data, the following adverse events were reported at any time in the inclisiran arm:

• Injection-site reactions: 8.2% inclisiran vs. 1.8% placebo
• Nasopharyngitis: 11.2% vs. 10.6% (not meaningfully different)
• Upper respiratory tract infection: 8.0% vs. 8.2% (not different)
• Back pain: 7.2% vs. 6.2%
• Arthralgia: 5.2% vs. 4.2%

No drug-related serious adverse events occurred with a frequency exceeding placebo. [4]

Statin Myopathy Is Not Worsened

One concern patients on high-intensity statins raise is whether adding another lipid-lowering agent increases muscle-related symptoms. In the Phase 3 program, myalgia rates were 3.9% in the inclisiran arm versus 4.7% in placebo. Inclisiran does not carry a myopathy warning. [2]

What Drives the Six-Month Dosing Interval

The longevity of inclisiran's effect comes from the RISC mechanism. Once loaded into RISC, the antisense strand of the siRNA is protected from nuclease degradation. The half-life of the RISC-loaded drug complex in hepatocytes has been estimated at roughly nine months in preclinical models, though the effective clinical duration is defined pragmatically as six months based on Phase 3 pharmacodynamic data. [1]

Pharmacokinetic Summary in Plain Numbers

Plasma half-life of inclisiran itself is approximately nine hours. The drug is essentially undetectable in plasma after 48 hours. The LDL-lowering effect, however, continues for 180 days because the active RISC complex persists intracellularly. Peak plasma concentration (Cmax) after a 284 mg subcutaneous dose is approximately 508 ng/mL, achieved at approximately four hours post-injection. [2]

What Happens if You Miss the Three-Month (Day 90) Dose

The Day 90 dose is a loading reinforcement. In the ORION trials, LDL-C reduction was approximately 38-42% at day 90 from a single injection, then climbed to the full 50% after the second injection. Missing the Day 90 dose by more than three months requires restarting from Day 1 per the prescribing information. [2]

How Inclisiran Fits Into Current Cardiovascular Guidelines

The American College of Cardiology and American Heart Association 2022 Guideline on Nonstatin Therapies lists PCSK9 inhibitors as a Class I recommendation for patients with clinical ASCVD and LDL-C at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe therapy. [5]

Where Inclisiran Sits vs. Monoclonal PCSK9 Inhibitors

The ACC/AHA guideline groups inclisiran with evolocumab and alirocumab on efficacy grounds, noting comparable LDL-C reduction magnitude. The differentiating factor is the dosing frequency. Two injections per year versus 26 injections per year (biweekly dosing) is a practical difference that drives adherence. A 2022 analysis in the Journal of the American College of Cardiology estimated that approximately 70% of patients on biweekly PCSK9 inhibitor dosing are adherent at 12 months, compared to modeled projections above 90% for twice-yearly regimens. [6]

The American College of Cardiology's Familial Hypercholesterolemia Clinical Guidance Document states: "Adherence to lipid-lowering therapy is the single largest modifiable factor determining cardiovascular outcomes in high-risk patients." [5]

Heterozygous Familial Hypercholesterolemia

In patients with heterozygous familial hypercholesterolemia (HeFH), baseline LDL-C is often 160 to 300 mg/dL even on maximum-dose statins. ORION-9 (N=482 HeFH patients) demonstrated a 39.7% time-averaged LDL-C reduction with inclisiran versus placebo (P<0.0001), with a day-510 LDL-C reduction of 47.9%. [7] HeFH patients may reach their first-month lipid panel at week four and see a 30 to 40 mg/dL drop from a 200 mg/dL baseline, which is real progress even before the full effect develops.

Practical Week-by-Week Calendar for Patients

Day 1 (Injection Day)

• Arrive at clinic; confirm current statin dose is unchanged
• Receive 284 mg inclisiran SC into abdomen, upper arm, or thigh
• Wait 15 minutes for observation
• Record injection site location in your patient portal
• No activity restrictions after leaving the clinic

Days 2 to 7

• Watch for injection-site redness, swelling, or warmth (expected and self-limited)
• Continue statin therapy without interruption
• No dietary changes required; inclisiran has no food interactions [2]
• No lipid test needed this week

Days 8 to 30

• LDL-C reduction is occurring but has not peaked
• Some providers obtain a lipid panel at 30 days for documentation; it will show partial reduction
• Continue any ezetimibe or bile acid sequestrant co-therapy without changes
• Mark Day 90 on your calendar now; that second injection is the pharmacodynamic "booster"

Day 90 (Second Injection)

• Second dose given in clinic
• After Day 90, subsequent doses are every six months (Day 270, Day 450, and so on)
• First full lipid panel typically ordered at or after Day 150 to capture the plateau

Comparing Inclisiran's First-Month Timeline to Other PCSK9 Agents

| Agent | Route / Frequency | LDL-C Reduction | Onset (50% effect) | |---|---|---|---| | Inclisiran (Leqvio) | SC, twice yearly | ~50% | Weeks 8-12 after dose 2 | | Evolocumab (Repatha) | SC, every 2 or 4 weeks | ~60% | Week 2-4 | | Alirocumab (Praluent) | SC, every 2 or 4 weeks | ~50-60% | Week 2-4 |

Evolocumab and alirocumab produce faster LDL-C reduction in month one because they block circulating PCSK9 protein immediately rather than waiting for existing PCSK9 mRNA turnover. That speed advantage is relevant only when the fastest possible reduction is the clinical priority, for example in an acute coronary syndrome setting. For stable outpatients, inclisiran's slower month-one onset does not translate to worse outcomes in the trial data. [4, 8]

Special Populations in the First Month

Chronic Kidney Disease

Inclisiran is not renally cleared to a significant degree; the kidney elimination fraction is less than 10%. In ORION-10, patients with eGFR as low as 30 mL/min/1.73m2 received the full 284 mg dose without dose adjustment. No first-month safety signal was observed in this subgroup. [4]

Older Adults (Age 65 and Above)

Approximately 40% of ORION-10 enrollees were 65 or older. LDL-C reductions in patients 65 and above were numerically similar to younger patients at all measured time points. No age-based dose adjustment is recommended. [2]

Women and Hormonal Therapy

No pharmacokinetic interaction between inclisiran and estrogen-based hormone therapy has been identified in the prescribing label. [2] Postmenopausal women on HRT who add inclisiran do not need hormone dose adjustments in the first month.

What Your Cardiologist Is Watching in Month One

Cardiologists experienced with inclisiran typically focus the first-month visit on confirming the injection was administered correctly, ruling out injection-site infection, and reviewing any new statin intolerance symptoms that might prompt a statin dose adjustment before the next inclisiran injection. The lipid panel at this visit is informational rather than decision-driving.

A 2023 real-world registry analysis from the European Atherosclerosis Society database (N=1,204 inclisiran-treated patients outside clinical trials) found that 68% of patients reached LDL-C <70 mg/dL after the first two-dose loading sequence, and 82% reached that target after 12 months. [9] Those numbers are directionally consistent with the ORION-10 key data but reflect real-world practice, including patients who may have had lower baseline LDL-C than the trial population.

The prescribing label's monitoring guidance is minimal by design: no routine liver function testing, no creatine kinase monitoring, and no renal panel required beyond standard cardiovascular risk management. [2]

For patients starting inclisiran today, the most evidence-based next step after completing month one is scheduling the Day 90 injection before leaving the clinic, because that second dose is what converts a partial LDL-C response into the sustained 50% reduction seen across 510 days in ORION-10.